Transfusion Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• P‐TS‐7 | An Evaluation of Plasma Transfusion Practices: A 10‐Year Retrospective Study 2023
• An evaluation of the clinical impacts of 7‐day platelets 2023
• Accuracy of International Classification of Diseases 10th Revision Codes for Transfusion-Related Immunomodulation Outcomes: Systematic Review and Meta-analysis 2021
• A Case of Leukocyte Adhesion Deficiency Type 2 Presenting with No Detectable H-Antigen or Anti-H Antibody 2020
• A Prospective Interventional Study of Blood Bank Technologist Screening of Red Blood Cell Orders 2020
• First-2: Prospective, Randomized Study Comparing Administration of Clotting Factor Concentrates with Standard Massive Hemorrhage Protocol in Severely Bleeding Trauma Patients 2020
• Platelet Transfusion Practice and Platelet Refractoriness: A Single Center Study for a Cohort of Pediatric Oncology Patients 2020
• Transfusion Reactions Following the Implementation of Seven Day Platelets 2020
• Malaria parasitemia among blood donors in Uganda 2020
• Blood Loss From Laboratory Testing in the Intensive Care Unit and Transfusion: A Retrospective Study 2019
• The FIBRES Randomized Controlled Noninferiority Trial of Fibrinogen Concentrates Versus Cryoprecipitate in Cardiac Surgery: Subgroup and Safety Analysis 2019
• Development of a "Gold Standard" Informed Consent Narrative for Blood Transfusion 2018
• Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies 2018
• Analysis of Red Blood Cell Storage Duration and in-Hospital Mortality Using Time Dependent Exposure: Is the Oldest Blood Bad? 2017
• Determining the Factors for Reassessment after Transfusion: A Canadian Survey 2017
• Antibodies of Undetermined Significance in Solid-phase Technology, Exploring Incidence, Associated Patient Factors and Laboratory Impact 2016
• Audit of Provincial IVIG Request Forms and Efficacy Documentation in Four Tertiary Care Centres in Canada 2016
• BloodBrief: Increasing Awareness to Influence Transfusion Practice 2016
• Developing a Data-driven Research Program: An Integrated Database Network Tool Driving Education and Research Forward 2016
• Extending Storage of Thawed Cryoprecipitate from 4 Hours to 24 Hours at 20 degrees C to 24 degrees C Poses a Safety Risk to Transfusion Patients 2016
• Group O Utilization Patterns: The GROUP Study 2016
• How Many AB Plasma Units Were Infused? The HABSWIN Study 2016
• Informing Fresh Versus Old Red Cell Management (INFORM) Trial: A Large International Pragmatic Randomized Trial 2016
• Red Cell Antigen Genotyping Compared to Serological Phenotyping in Sickle Cell Disease Patients in Canada: Potential for Reducing Alloimmunization 2016
• Transfusion Premedication Practices in Pediatrics: Results of a Canadian Survey 2016
• Understanding Hospital Inventory 2016
• A Repeat Provincial Audit of Frozen Plasma (FP) and Prothrombin Complex Concentrates (PCCs) 2015
• Clinical Efficacy and Safety of Platelets in Additive Solution Treated With Two Commercial Pathogen Reduction Technologies 2015
• Exploratory Analysis of a Blood Processing Method and In-hospital Mortality 2015
• Exploratory Analysis of the Association Between Donor Sex and Inhospital Mortality in Transfusion Recipients 2015
• Group O Red Blood Cells: Where is Universal donor blood Being Used? 2015
• Group O and RhD=Negative Utilization Patterns and Associated Hospital Policies: A Multicenter, International Study 2015
• Intraosseous Specimens: Suitable for Pretransfusion Testing in Trauma? 2015
• Quantification of Cell-free DNA in Red Blood Cell Concentrates Produced via Buffy Coat or Whole Blood-Filtered Methods 2015
• Red Blood Cell Transfusion Antigen Matching Influence on Gestational Outcomes (AMIGO) Study 2015
• Survival Following Ultra-massive Transfusion (UMT): A Review Of 1360 Cases 2015
• A Retrospective Review of Platelet Refractoriness in a Cohort of Pediatric Oncology Patients 2014
• Donath-Landsteiner Testing: A Retrospective Review of Testing During Seven Years at a Large Academic Health Center and Results of a National Survey 2014
• Transfused Plasma Lacking Factor VIII (FVIII) but not Fibrinogen Restores Hemostasis in Coagulopathic Mice 2014
• An Epidemiological Cohort Study of Blood Transfusion Practices Among a Population of Pediatric Oncology Patients 2012
• High Rates of Inappropriate Frozen Plasma Utilization Based on Expert Medical Rating; Results of a Multicentre Canadian Study 2012
• Mortality, Blood Storage Duration, and Method of Red Cell Production: An Exploratory Analysis 2012
• Prothrombin Complex Concentrates Reduce Blood Loss in Mice Rendered Coagulopathic by Warfarin but Not Dabigatran Etexilate 2012
• A Pilot Study Evaluating the Effects of Intravenous Immunoglobulin (IVIG) Administration on Serological Test Results and Adverse Events 2011
• Association Between HLA Class I and Class II Alleles and the Outcome of West Nile Virus Infection: An Exploratory Study 2011
• Can We Do a 25,000 Patient Pragmatic Study to Address the Age of Blood and Mortality Controversy? A Pilot to Determine Feasibility 2011
• Utilizing Automation to Improve Blood Product Delivery to Patients 2011
• Equivalent Plasma Quality of Canadian Blood Services' Frozen Plasma Leukoreduced by Centrifugation or Filtration 2010
• A Mouse Model to Assess the Efficacy of Plasma Transfusion in the Prevention of Bleeding 2009
• Differences Between Frozen Plasmas Produced by the Buffy Coat Method of Whole Blood Processing and Leukoreduced by Centrifugation or Filtration 2009
• Duration of Red Cell Storage and In-hospital Mortality in Patients with Cardiovascular Disease 2009
• Evidence of Patient Specific HLA Antibodies in Canadian TRALI Cases Classified by the 2004 Canadian Consensus Conference Definition 2009
• Impact of Just In Time (JIT) Delivery of Blood Products on the Crossmatch/Transfusion (C/T) Ratio 2009
• Laboratory Information System - The Key Enabler to Consolidating Transfusion Services 2009
• TRALI Prevention at Canadian Blood Services: The Evolving Process and Its Impact on TRALI Cases in Canada 2009
• The Development of a Bleeding Severity Measurement Scale (BSMS): A New Measurement Tool 2009
• Development of a mouse model for assessing the efficacy of plasma transfusion in reducing bleeding 2008
• Evaluation of cardiac testing at decreased temperature 2008
• Fresh frozen plasma (FFP) sampled from segments differs in coagulation factor assays from FFP sampled from the same bag 2008
• Implementation of just in time delivery of blood products in a multi-site academic facility 2008
• Loss of ATP secretion contributes to the decreased responses of stored platelets to thrombin 2008
• Oral administration of FVIII DNA as a potential treatment for hemophilia A 2008
• Refractory thrombotic thrombocytopenic purpura in a patient with waldenstroms macroglobulinemia 2008
• Transfused human alpha-1-acid glycoprotein attenuates hepatic inflammation in mice more effectively than human albumin 2008
• Two years' national experience of quality monitoring of Canadian frozen plasma products 2008
• Use of automated monitor/mixer for collecting whole blood units 2008
• Use of the medical event reporting system to track sample labeling errors and wrong blood in tube 2008
• Pathogen inactivation: making decisions about new technologies 2007
• A systematic review and meta-analysis of platelets prepared from apheresis versus whole blood 2007
• Do transfusion committees meet their objectives? 2007
• A Pre/Post observational study of the impact on transfusion reactions by the implementation of the 'Buffy Coat' method 2006
• A management tool to track platelet inventory patterns and wastage in 26 hospitals 2006
• Development of a conceptual model to describe the experience of permanent donor deferral 2006
• Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura: A case report 2006
• Results of Anti-HBc screening of blood donors at Canadian blood services - One year of testing 2006
• Factors affecting red cell transfusion decisions during coronary artery bypass surgery: A national survey 2005
• Insights into the risk of bleeding in thrombocytopenic patients with acute leukemia 2005
• Patient self-assessment of bleeding symptoms 2005
• The cost of "utilization" and "wastage" of red blood cells and platelets in a Canadian regional laboratory program 2005
• A randomized crossover trial comparing in-vivo platelet recovery and survival of leukoreduced apheresis and whole blood derived platelets 2004
• Either reducing or increasing the molecular volume of recombinant factor IX accelerates its overall clearance in a mouse model of Hemophilia B 2004
• Identifying the optimal red cell transfusion threshold for extremely low birth weight infants: The premature in need of transfusion (PINT) study 2004
• Auditing of hospital armband identification practices in four acute care hospitals 2003
• Comparison of methods for the analysis of bleeding outcomes in platelet transfusion studies 2003
• Evaluation of a bacteria detection system using whole blood derived platelets stored individually and as a pool for up to 7 days 2003
• Phase 1 results from a transfusion committee research project: The status of transfusion committees in Ontario hospitals 2003
• Severe hypotension following transfusion of pre-storage leukoreduced red blood cells and acute normovolemic hemodilution whole blood 2003
• Success in achieving a targeted platelet dose: What dose are we actually giving? 2003
• Use of recombinant forms of Duffy blood group antigen to detect anti-Fy(a) and anti-Fy(b) antibodies 2003
• Window period HIV in a test-seeking blood donor: First p24 antigen positive donor in Canada without detectable anti-HIV antibodies 2003
• A survey of blood collection activities in hospital transfusion services. 2002
• Evaluation of whole blood derived platelets stored as a pool for 7 days. 2002
• The role of intravenous immunoglobulin in the management of severe early onset antenatal RBC allommunization. 2002
• Vein to vein tracking system for factor concentrates. 2002
• A feasibility pilot study using medical records and laboratory information systems to address blood utilization issues 2001
• A study to determine the accuracy of transfusion coding by hospital medical records departments 2001
• Detection of mixed field reactions in ABO groupings and Rh typings 2001
• Fusion to albumin alters the clearance of factor IX in vivo 2001
• Pilot study to determine baseline transfusion medicine knowledge of nurses working on a Hematology/Oncology Service 2001
• Team development project in an academic transfusion medicine service 2001
• Cleavage of protease-activated receptor 1(PAR-1) by a platelet protease and thrombin: Modulation by soybean trypsin inhibitor, glycoprotein IB(GPIB), and anti-protease-activated receptor antibodies. 2000
• Comparison of post transfusion platelet response following random donor and apheresis platelets 2000
• Evaluation of clot formation in AS-3 red cells diluted with Ringer's Lactate 2000
• Prevention of febrile non-hemolytic transfusion reactions in children: A randomized controlled trial 2000
• Production of a recombinant factor IX-albumin fusion protein 2000
• Therapeutic levels of human factor VIII in mice implanted with encapsulated recombinant myoblasts: Potential for gene therapy of hemophilia A 2000
• A randomized trial comparing plasma removal to two types of pre-storage leukoreduction to prevent reactions to platelets 1999
• Acute reactions to platelets: A new classification and interobserver reliability studies. 1998
• Diagnosis of heparin-induced thrombocytopenia (HIT): Comparison of methods. 1998
• Face validity of a new classification for platelet reactions. 1998
• Parental directed donations reduce allogeneic blood exposure in neonatal intensive care. 1998
• Comparison of gel and tube techniques for direct antiglobulin tests 1997
• A comparison of two interventions to prevent platelet reactions. 1996
• The effect of blood product preparation on cytokine levels. 1996
• VENOUS LIMB GANGRENE COMPLICATING HEPARIN-INDUCED THROMBOCYTOPENIA - IMPLICATIONS FOR TRANSFUSION MEDICINE 1995
• 2 EPISODES OF NONCARDIOGENIC PULMONARY-EDEMA IN A PATIENT CAUSED BY THE SAME DONORS BLOOD 1994
• PLATELET REACTIONS CAUSED PRIMARILY BY PLASMA SUPERNATANT 1993
• RISK OF ALLOIMMUNIZATION AND TRANSFUSION IN HIGH-RISK OBSTETRICAL PATIENTS 1993
• BLOOD PRODUCT AGE PREDICTS TRANSFUSION REACTIONS (TR) 1992
• THE IMPACT OF MONOCLONAL AB PURIFIED PLASMA DERIVED FVIII ON IMMUNE STATUS IN HEMOPHILIA-A PATIENTS 1991
• A COST-EFFECTIVENESS EVALUATION OF PLATELET AND HLA MATCHING IN THE MANAGEMENT OF ALLOIMMUNIZED THROMBOCYTOPENIC PATIENTS 1987
• HYPERGAMMAGLOBULINEMIA CAN BE ASSOCIATED WITH A POSITIVE DIRECT ANTIGLOBULIN-TEST, A NON-REACTIVE ELUATE, AND NO EVIDENCE OF HEMOLYSIS 1985
• AN APPROACH TO DETERMINE OPTIMAL HB STANDARDS FOR BLOOD-DONORS 1984
• BLOOD-TRANSFUSIONS AND COLORECTAL-CANCER RECURRENCE - A POSSIBLE RELATIONSHIP 1983
• PLASMA FIBRONECTIN LEVEL AND CLINICAL STATUS IN CARDIAC-SURGERY PATIENTS 1982
• THE MECHANISM OF MALARIA-INDUCED IMMUNE THROMBOCYTOPENIA 1982
• MEASUREMENT OF PLATELET-ASSOCIATED IGG IS OF LIMITED USEFULNESS IN THE DIAGNOSIS OF IDIOPATHIC THROMBOCYTOPENIC PURPURA 1981
• THE PRENATAL PREDICTION OF INFANT PLATELET COUNT IN MOTHERS WITH SUSPECTED AUTOIMMUNE THROMBOCYTOPENIA 1981
• THE PRODUCTION OF PLATELET CONTROLS FOR ASSAYS QUANTITATING PLATELET-ASSOCIATED IGG (PAIGG) 1981
• DEVELOPMENT AND ASSESSMENT OF AN I125 ANTI-IGG ANTIGLOBULIN CONSUMPTION ASSAY FOR MEASURING PLATELET ASSOCIATED IGG (PAIGG) 1980
• THE AMOUNT OF BLOOD-GROUP A-ANTIGEN, B-ANTIGEN ON PLATELETS IS PROPORTIONAL TO THE AMOUNT THAT IS FREE IN THE PLASMA 1980
• THE MAJORITY OF PLATELET ASSOCIATED IGG (PAIGG) IS IN THE INTERIOR OF PLATELETS AND NOT MEASURABLE USING STANDARD ASSAYS 1980
• ABSENCE OF HEMOLYSIS OF T-ACTIVATED RED-CELLS FOLLOWING INFUSION OF BLOOD PRODUCTS 1978
• ABSENCE OF HEMOLYSIS OF T-ACTIVATED RED-CELLS FOLLOWING INFUSION OF BLOOD PRODUCTS 1977
• Privacy-preserving federated data access and federated learning: Improved data sharing and AI model development in transfusion medicine. 2024
• Current state of undergraduate medical school training in transfusion medicine and its impact on postgraduate trainee knowledge.  64:1407-1413. 2024
• Reducing blood product wastage through the inter‐hospital redistribution of near‐outdate inventory.  64:1207-1216. 2024
• Quality of life and cost‐effectiveness of convalescent plasma compared to standard care for hospitalized COVID‐19 patients in the CONCOR‐1 trial.  64:606-614. 2024
• Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE.  64:223-235. 2024
• An unsupervised learning approach to identify immunoglobulin utilization patterns using electronic health records.  63:2234-2247. 2023
• P‐BB‐8 | A Survey to Understand C1 Esterase Inhibitor Distribution Patterns and Use in Canada.  63:94A-95A. 2023
• P‐TS‐10 | An Unsupervised Learning Approach to Identify Immunoglobulin Utilization Patterns Using Electronic Health Records.  63:261A-262A. 2023
• P‐TS‐29 | Effect of Donor and Recipient Characteristics on Hemoglobin Increments in Intensive Care Unit Patients Receiving Red Blood Cell Transfusion.  63:274A-274A. 2023
• SARS‐CoV‐2 seroprevalence among blood donors in Uganda: 2019–2022.  63:1354-1365. 2023
• Erratum.  63:1412-1412. 2023
• Transfusion camp: A retrospective study of self‐reported impact on postgraduate trainee transfusion practice.  63:839-848. 2023
• KEL1 negative red cell transfusions for females of current or future child‐bearing potential: A clinical impact and feasibility study.  63:59-68. 2023
• A data‐informed system to manage scarce blood product allocation in a randomized controlled trial of convalescent plasma.  62:2525-2538. 2022
• Clinical and laboratory predictors of fetal and neonatal alloimmune thrombocytopenia.  62:2213-2222. 2022
• Continuing Medical Education.  62:2212-2212. 2022
• A data‐driven approach to determine daily platelet order quantities at hospitals.  62:2048-2056. 2022
• Hospital red blood cell and platelet supply and utilization from March to December of the first year of the COVID‐19 pandemic: The BEST collaborative study.  62:1559-1570. 2022
• Minimal impact of anticoagulant on in vitro whole blood quality throughout a 35‐day cold‐storage regardless of leukoreduction timing.  62:S98-S104. 2022
• Database‐driven research and big data analytic approaches in transfusion medicine.  62:1427-1434. 2022
• Transfusion thresholds in myelodysplastic syndrome—Helping patients live better.  62:1313-1314. 2022
• Transfusion practice in the bleeding critically ill: An international online survey—The TRACE‐2 survey.  62:324-335. 2022
• Reduction of blood group A antigen on erythrocytes in a patient with myelodysplastic syndrome harboring somatic mutations in RUNX1 and GATA2.  62:469-480. 2022
• Rejuvenated and safe: Freeze‐dried plasma for the 21st century.  62:257-260. 2022
• Retention of hemostatic and immunological properties of frozen plasma and COVID‐19 convalescent apheresis fresh‐frozen plasma produced and freeze‐dried in Canada.  62:418-428. 2022
• From demand forecasting to inventory ordering decisions for red blood cells through integrating machine learning, statistical modeling, and inventory optimization.  62:87-99. 2022
• Necrotizing enterocolitis and mortality after transfusion of ABO non‐identical blood.  61:3094-3103. 2021
• The safety of COVID‐19 convalescent plasma donation: A multi‐institutional donor hemovigilance study.  61:2668-2676. 2021
• Cold‐stored leukoreduced whole blood: Extending the time between donation and filtration has minimal impact on in vitro quality.  61:S131-S143. 2021
• Pathogen reduction of whole blood: Supplementing fibrinogen partly corrects clot formation in a massive transfusion model.  61:1884-1893. 2021
• Circulating heparin‐like anticoagulants: Case report and review of literature.  61:968-973. 2021
• A prospective multi‐faceted interventional study of blood bank technologist screening of red blood cell transfusion orders: The START study.  61:410-422. 2021
• Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy.  61:286-293. 2021
• Cluster‐randomized trials in transfusion medicine.  60:2470-2473. 2020
• Revisiting study design and methodology for pathogen reduced platelet transfusions: a round table discussion.  60:1604-1611. 2020
• A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets.  60:1267-1277. 2020
• Blood loss from laboratory testing, anemia, and red blood cell transfusion in the intensive care unit: a retrospective study.  60:256-261. 2020
• RUNX1 mutation in a patient with myelodysplastic syndrome and decreased erythrocyte expression of blood group A antigen.  60:184-196. 2020
• Premedication for the prevention of nonhemolytic transfusion reactions: a systematic review and meta‐analysis.  59:3609-3616. 2019
• The safety and efficacy of ferumoxytol in the treatment of iron deficiency: a systematic review and meta‐analysis.  59:3646-3656. 2019
• Is donating blood for the faint of heart? a systematic review of predictors of syncope in whole blood donors.  59:2865-2869. 2019
• Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee.  59:2733-2748. 2019
• The successful implementation of an automated institution‐wide assessment of hemoglobin and ABO typing to dynamically estimate red blood cell inventory requirements.  59:2203-2206. 2019
• Autoimmune heparin‐induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.  59:1924-1933. 2019
• The association between platelet transfusions and mortality in patients with critical illness.  59:1962-1970. 2019
• Transfusion Camp: a prospective evaluation of a transfusion education program for multispecialty postgraduate trainees.  59:2141-2149. 2019
• International assessment of massive transfusion protocol contents and indications for activation.  59:1637-1643. 2019
• Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion.  59:1850-1856. 2019
• Electronic patient identification for sample labeling reduces wrong blood in tube errors.  59:972-980. 2019
• The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis.  59:482-491. 2019
• What's in a name? Patient registration errors and their threat to transfusion safety.  58:3035-3036. 2018
• Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin.  58:2729-2735. 2018
• Top 10 mistakes made in research.  58:2478-2482. 2018
• Neutropenia and monocytopenia in recurrent anaphylactoid reactions after red blood cell transfusions in a woman with immunoglobulin A (IgA) deficiency and anti‐IgA.  58:2320-2325. 2018
• Knowledge translation in transfusion medicine. Part 4: Measurement and sustainability of knowledge use.  58:2104-2107. 2018
• Knowledge translation in transfusion medicine. Part 3: Interventions and tools.  58:1835-1837. 2018
• Knowledge translation in transfusion medicine. Part 2: Selecting the knowledge and identifying the barriers.  58:1097-1099. 2018
• Critical developments of 2017: a review of the literature from selected topics in transfusion. A committee report from the AABB Clinical Transfusion Medicine Committee.  58:1065-1075. 2018
• Knowledge translation in transfusion medicine. Part 1: The basics and the frameworks.  58:629-632. 2018
• An international investigation into AB plasma administration in hospitals: how many AB plasma units were infused? The HABSWIN study.  58:151-157. 2018
• An international investigation into O red blood cell unit administration in hospitals: the GRoup O Utilization Patterns (GROUP) study.  57:2329-2337. 2017
• From cytokines to pragmatic designs: changing paradigms.  57:2298-2306. 2017
• Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study.  57:525-532. 2017
• Pathogen inactivation by riboflavin and ultraviolet light illumination accelerates the red blood cell storage lesion and promotes eryptosis.  57:661-673. 2017
• Warm‐reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: review of the literature and survey of current practice.  57:463-477. 2017
• Paroxysmal cold hemoglobinuria: a difficult diagnosis in adult patients.  57:137-143. 2017
• Interpreting trial sequential analysis.  56:2918-2922. 2016
• Risk‐based decision making and ethical considerations in donor compensation for plasma‐derived medicinal products.  56:2889-2894. 2016
• Evaluating appropriate red blood cell transfusions: a quality audit at 10 Ontario hospitals to determine the optimal measure for assessing appropriateness.  56:2466-2476. 2016
• Red blood cell transfusion: 2016 clinical practice guidelines from AABB.  56:2627-2630. 2016
• Letter of response to Peters and Vlaar commentary.  56:2395-2397. 2016
• Transfusion premedication practices among pediatric health care practitioners in Canada: results of a national survey.  56:2296-2302. 2016
• Platelet transfusion therapy in sub‐Saharan Africa: bacterial contamination, recipient characteristics, and acute transfusion reactions.  56:1951-1959. 2016
• An evaluation of overall effectiveness and treatment satisfaction with intravenous immunoglobulin among patients with immune thrombocytopenia.  56:1739-1744. 2016
• AABB Committee Report: reducing transfusion‐transmitted cytomegalovirus infections.  56:1581-1587. 2016
• Erratum.  56:1249-1249. 2016
• Producing megakaryocytes from a human peripheral blood source.  56:1066-1074. 2016
• Sustained and significant increase in reporting of transfusion reactions with the implementation of an electronic reporting system.  56:1247-1248. 2016
• Triplets with neonatal alloimmune thrombocytopenia due to antibodies against human platelet antigen 1a.  56:1166-1170. 2016
• CONSORT and clinical trial reporting: room for improvement.  56:781-783. 2016
• Exposure to ABO‐nonidentical blood associated with increased in‐hospital mortality in patients with group A blood.  56:550-557. 2016
• Survival after ultramassive transfusion: a review of 1360 cases.  56:558-563. 2016
• Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.  56:73-79. 2016
• 2015 proceedings of the National Heart, Lung, and Blood Institute's State of the Science in Transfusion Medicine symposium.  55:2282-2290. 2015
• A benchmarking program to reduce red blood cell outdating: implementation, evaluation, and a conceptual framework.  55:1621-1627. 2015
• The prevalence of anti‐K in Canadian prenatal patients.  55:1486-1491. 2015
• Blood utilization at a national referral hospital in sub‐Saharan Africa.  55:1058-1066. 2015
• Splitting versus lumping: reconsidering the definition of transfusion‐related acute lung injury.  55:927-929. 2015
• The fibrinogen but not the Factor VIII content of transfused plasma determines its effectiveness at reducing bleeding in coagulopathic mice.  55:1040-1050. 2015
• The transfusion‐related acute lung injury controversy: lessons from heparin‐induced thrombocytopenia.  55:1128-1134. 2015
• Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method.  55:815-823. 2015
• Exploratory studies on the age of transfused blood and in‐hospital mortality in patients with cardiovascular diagnoses.  55:364-372. 2015
• Plasma transfusion trials and tribulations.  55:14-16. 2015
• An epidemiologic cohort study reviewing the practice of blood product transfusions among a population of pediatric oncology patients.  54:2736-2744. 2014
• Effects of placental transfusion in extremely low birthweight infants: meta‐analysis of long‐ and short‐term outcomes.  54:1192-1198. 2014
• Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin.  54:640-645. 2014
• Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw.  54:418-425. 2014
• Recruitment and retention of blood donors in four Canadian cities: an analysis of the role of community and social networks.  53:180S-184S. 2013
• Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.  53:2807-2812. 2013
• Utilization of frozen plasma in Ontario: a provincewide audit reveals a high rate of inappropriate transfusions.  53:2222-2229. 2013
• Processing residual pump blood using ultrafiltration during cardiovascular surgery.  53:2107-2108. 2013
• Clinical trials evaluating pathogen‐reduced platelet products: methodologic issues and recommendations.  53:1843-1855. 2013
• Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial.  53:1487-1492. 2013
• The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions.  53:1531-1543. 2013
• A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative.  53:1328-1334. 2013
• Leaving nothing to chance: how to randomize a clinical trial.  52:2513-2515. 2012
• Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura.  52:2517-2523. 2012
• A new tool to assess bleeding severity in patients with chemotherapy‐induced thrombocytopenia (CME).  52:2466-2474. 2012
• Continuing Medical Education Program in Transfusion.  52:2465-2465. 2012
• Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST).  52:1687-1695. 2012
• Old blood bad? Either the biggest issue in transfusion medicine or a nonevent.  52:1165-1167. 2012
• The effect of blood storage duration on in‐hospital mortality: a randomized controlled pilot feasibility trial.  52:1203-1212. 2012
• The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop.  52:1363-1378. 2012
• Changes in coagulation factor activity and content of di(2‐ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing.  52:493-502. 2012
• Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation.  52:529-536. 2012
• Forecasting Ontario's blood supply and demand.  52:366-374. 2012
• Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges.  51:2304-2310. 2011
• Bias in transfusion research: from study design to result reporting.  51:237-240. 2011
• Time to rethink clinically important outcomes in platelet transfusion trials.  51:430-434. 2011
• Composite outcomes in clinical trials: what are they and when should they be used?.  51:11-13. 2011
• Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia.  50:2577-2581. 2010
• A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.  50:2362-2375. 2010
• A systematic assessment of the quality of reporting for platelet transfusion studies.  50:2135-2144. 2010
• Practices associated with ABO‐incompatible platelet transfusions: a BEST Collaborative international survey.  50:1743-1748. 2010
• Transfusion premedication to prevent acute transfusion reactions: a retrospective observational study to assess current practices.  50:1722-1730. 2010
• Posttransfusion platelet count increments after ABO‐compatible versus ABO‐incompatible platelet transfusions in noncancer patients: an observational study.  50:1552-1560. 2010
• The randomized controlled trial: in celebration of TRANSFUSION's 50th.  50:1173-1178. 2010
• Conversion to the buffy coat method and quality of frozen plasma derived from whole blood donations in Canada.  50:1043-1049. 2010
• Sporadic formation of cryoprecipitate‐like particulate matter in thawed fresh‐frozen plasma units.  50:949-950. 2010
• Life‐threatening hemolytic anemia due to an autoanti‐Pr cold agglutinin: evidence that glycophorin A antibodies may induce lipid bilayer exposure and cation permeability independent of agglutination.  50:292-301. 2010
• Studies of the anti–platelet factor 4/heparin immune response: adapting the enzyme‐linked immunosorbent spot assay for detection of memory B cells against complex antigens.  50:32-39. 2010
• Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies.  49:2276-2284. 2009
• Reviewing manuscripts: tips and responsibilities.  49:2265-2268. 2009
• Measuring and reporting the effect of an intervention: absolute measures.  49:2022-2023. 2009
• Measuring and reporting the effect of an intervention: absolute measures.  49:2022-2023. 2009
• ERRATA.  49:2012-2012. 2009
• Immune mechanisms in heparin‐induced thrombocytopenia: no evidence for immunoglobulin M anti‐idiotype antibodies.  49:1812-1818. 2009
• Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses (vol 46, pg 1286, 2006).  49:2012-2012. 2009
• Pilot trials in transfusion medicine.  49:1293-1295. 2009
• Suboptimal effect of a three‐factor prothrombin complex concentrate (Profilnine‐SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.  49:1171-1177. 2009
• CONSORT comes to TRANSFUSION.  49:194-195. 2009
• Factors affecting the frequency of red blood cell outdates: an approach to establish benchmarking targets.  49:219-226. 2009
• Measuring and reporting the effect of an intervention: relative measures.  49:9-12. 2009
• A policy informing qualitative study to improve the process of blood product recalls and withdrawals.  48:2585-2595. 2008
• Box plots: use and interpretation.  48:2279-2280. 2008
• Errors in patient specimen collection: application of statistical process control.  48:2143-2151. 2008
• Consequences of transfusion of platelet antibody: a case report and literature review.  48:1981-1989. 2008
• The use and abuse of surrogate endpoints in clinical research in transfusion medicine.  48:1547-1549. 2008
• Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review.  48:1447-1458. 2008
• Transfusion‐related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.  48:814-821. 2008
• A multicenter pilot‐randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation.  48:81-91. 2008
• A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia.  48:92-98. 2008
• Understanding the meaning of permanent deferral for blood donors.  48:64-72. 2008
• Designing laboratory‐based research studies: is it time for a change?.  47:2336-2337. 2007
• Treatment allocation in clinical trials.  47:2187-2188. 2007
• Variability and predictability of large‐volume red blood cell transfusion in cardiac surgery: a multicenter study.  47:2081-2088. 2007
• Randomization in clinical trials.  47:1753-1754. 2007
• The science of systematic reviews.  47:1347-1349. 2007
• Prevention of bedside errors in transfusion medicine (PROBE‐TM) study: a cluster‐randomized, matched‐paired clinical areas trial of a simple intervention to reduce errors in the pretransfusion bedside check.  47:771-780. 2007
• A revised classification scheme for acute transfusion reactions.  47:621-628. 2007
• Clinical research design and reporting: always room for improvement!.  47:2-3. 2007
• The research question.  47:15-17. 2007
• A study of the agreement between patient self‐assessment and study personnel assessment of bleeding symptoms.  46:1926-1933. 2006
• Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses.  46:1286-1291. 2006
• A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia.  46:903-911. 2006
• Helping me, helping you: self‐referencing and gender roles in donor advertising.  46:996-1005. 2006
• Which patients to include in the analysis?.  46:881-884. 2006
• Systematic underestimation of anemia severity in postoperative patients.  46:317-318. 2006
• In vivo recovery and survival of apheresis and whole blood‐derived platelets: a paired comparison in healthy volunteers.  46:257-264. 2006
• Five percent albumin for adult burn shock resuscitation: lack of effect on daily multiple organ dysfunction score.  46:80-89. 2006
• Five percent albumin for adult burn shock resuscitation: lack of effect on daily multiple organ dysfunction score.  46:80-89. 2006
• Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review.  45:1640-1657. 2005
• Assessing the effectiveness of whole blood–derived platelets stored as a pool: a randomized block noninferiority trial.  45:896-903. 2005
• In vitro evaluation of prestorage pooled leukoreduced whole blood–derived platelets stored for up to 7 days.  45:904-910. 2005
• Autologous peripheral blood progenitor cells are a potential source of parvovirus B19 infection.  45:394-398. 2005
• Understanding Canadian student motivations and beliefs about giving blood.  45:149-161. 2005
• Toward an understanding of transfusion‐related acute lung injury: statement of a consensus panel.  44:1774-1789. 2004
• Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage.  44:1361-1366. 2004
• Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers.  44:1135-1142. 2004
• Universal leukoreduction and acute transfusion reactions: putting the puzzle together.  44:1-4. 2004
• Role of the Hct in the treatment of thrombocytopenic patients.  43:1761-1762. 2003
• The above letter was sent to Heddle et al.: Dr Heddle offered the following reply.  43:1763-1763. 2003
• Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies.  43:742-752. 2003
• Developing a tracking system for coagulation factor concentrates in southern Ontario.  43:556-562. 2003
• The causes and treatment of reactions to platelet transfusions.  43:291-292. 2003
• Reply.  42:1524-1525. 2002
• Evidence‐based clinical reporting: a need for improvement.  42:1106-1110. 2002
• Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction.  42:753-758. 2002
• A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets.  42:556-566. 2002
• Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: will recent insight into pathogenesis translate into better treatment?.  42:388-392. 2002
• A second example of a transfusion‐associated septic reaction associated with Clostridium perfringens.  41:427-428. 2001
• RBC T activation and hemolysis: implications for pediatric transfusion management.  40:801-812. 2000
• A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets.  39:231-238. 1999
• Maternal immunization to Gov system alloantigens on human platelets.  37:823-828. 1997
• A simple and rapid competitive enzyme‐linked immunosorbent assay to identify HPA‐1a (Pl^A1)‐negative donor platelet units.  36:805-808. 1996
• The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates.  35:548-551. 1995
• The role of ABO compatibility in red cell alloimmunization during pregnancy.  34:360-361. 1994
• Platelet concentrates stored for 5 days in a reduced volume of plasma maintain hemostatic function and viability.  34:44-47. 1994
• A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions.  33:794-797. 1993
• THE VALUE OF POSTOPERATIVE RED-CELL TRANSFUSIONS IS UNCLEAR - REPLY.  33:623-623. 1993
• The value of postoperative red cell transfusions is unclear.  33:622-623. 1993
• A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy.  33:217-220. 1993
• A randomized trial on the efficacy of an autologous blood drainage and transfusion device in patients undergoing elective knee arthroplasty.  32:742-746. 1992
• Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange.  32:710-714. 1992
• A cost‐effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients.  29:201-207. 1989
• A prospective study evaluating the lowering of hemoglobin standards for blood donors.  29:268-272. 1989
• Hypergammaglobulinemia can be associated with a positive direct antiglobulin test, a nonreactive eluate, and no evidence of hemolysis.  28:29-33. 1988
• Anti‐Lu17.  26:306-306. 1986
• The effect of mode of agitation and type of plastic bag on storage characteristics and in vivo kinetics of platelet concentrates.  26:125-130. 1986
• Platelet survival studies, An overview of the factors affecting the efficiency and reliability of platelet radiolabeling.  26:19-22. 1986
• Granulocytes do not have surface ABO antigens.  25:567-569. 1985
• An approach to determine objectively minimum hemoglobin standards for blood donors.  25:286-288. 1985
• Quantitation of red cell‐associated IgG using an immunoradiometric assay.  24:473-476. 1984
• Acquired alteration in the expression of blood groups in a patient with sideroblastic anemia and chronic renal failure.  24:8-12. 1984
• The production of platelet controls for assays quantitating platelet‐associated IgG.  23:516-518. 1983
• Collection of erythroid progenitor cells by cytapheresis of peripheral blood of normal donors.  22:388-391. 1982
• Assessment of the optimal anticoagulant solution for storage of whole blood samples prior to measurement of platelet‐associated IgG.  22:295-297. 1982
• Antibodies to IGA in Pregnancy and in Recipient of Rh_o(D) Immune Globulin (Human).  12:394-399. 1972

has subject area

• 1102 Cardiorespiratory Medicine and Haematology (FoR)
• 1103 Clinical Sciences (FoR)
• 1107 Immunology (FoR)
• Cardiovascular System & Hematology (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 0041-1132
• 1537-2995

Electronic International Standard Serial Number (EISSN)

• 1537-2995